Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
36 participants
INTERVENTIONAL
2020-02-14
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Milk Protein Concentrate on Overall Health During Weight Loss in Overweight/Obese Adults
NCT01692860
Dairy Modulation of Oxidative and Inflammatory Stress in Overweight and Obese Subjects
NCT00948038
Dairy Attenuation of Metabolic Disease
NCT01266330
Resistance Exercise and Muscle Protein Synthesis in Obese Adults
NCT03411681
Effects of Increased, Egg-Based Protein Intake on Muscle Composition,
NCT01396915
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Full-fat dairy
3x daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
Controlled-Feeding Intervention
All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
Full-fat milk
3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
Non-fat diary
3x daily servings (cup-eq) of non-fat (0%) commercial cow's milk.
Controlled-Feeding Intervention
All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
Fat-free milk
3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.
Non-dairy control
3x daily servings (cup-eq) of non-dairy sourced macronutrient composition of full-fat milk.
Controlled-Feeding Intervention
All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
Non-dairy beverage
Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Controlled-Feeding Intervention
All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
Non-dairy beverage
Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.
Full-fat milk
3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
Fat-free milk
3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 40-59
* Pre-menopausal
* Sedentary/insufficiently active for prior 6 months (mo)
* Weight stable for prior 6 mo
Exclusion Criteria
* Alcohol consumption \>10 drinks per week
* Metabolic disorders (e.g., Metabolic Syndrome, Diabetes, thyroid diseases)
* Cardiovascular disease, arrhythmias
* Hypogonadism
* Asthma
* History of uncontrolled hypertension
* Orthopedic injury/surgery (within 1 yr)
* Hepatorenal, musculoskeletal, autoimmune, or neurological disease
* History of neuromuscular problems
* Previous participation in amino acid tracer studies
* Predisposition to hypertrophic scarring or keloid formation
* Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation
* Consumption of thyroid, androgenic, or other medications known to affect endocrine function
* Consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication)
* Pregnancy
* Allergy to dairy product or lactose intolerance
* Fasting plasma glucose (FPG) ≥ 126 mg/dL
* Oral glucose tolerance test (OGTT) ≥ 200 mg/dL
40 Years
59 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Illinois at Urbana-Champaign
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nicholas Burd
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Freer Hall
Urbana, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20173
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.